(firstQuint)Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer.

 65 patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach will be treated with 20mg/m2 Cabazitaxel for a maximum of 6 cycles.

 Main objective of the study is the Disease Control Rate (DCR) with Cabazitaxel.

.

 Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer@highlight

Single-arm study to determine disease control rate in second- (or later) line treatment with cabazitaxel after the failure of palliative primary treatment.

